Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adequate complete blood counts, liver and renal function~* 12-lead electrocardiogram (ECG) within normal limits~* Female subjects of child bearing potential agreeing to use a protocol specified method of contraception~* Male subjects agreeing to use protocol specified methods of contraception~* Willing to provide written informed consent and willing to comply with study requirements~Exclusion Criteria:~* Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection~* Parts A and B of the study: Used prescription medications within 14 days or 7 half-lives of administration of the first dose of study drug.~* History of meningococcal infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ALN-CC5 (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).